logo
Share SHARE
FONT-SIZE Plus   Neg

Valeant Pharma To Take Earnings Hit On Mylan's Zovirax Generic Launch

Canadian drug maker Valeant Pharmaceuticals International, Inc. (VRX,VRX.TO) announced Thursday that it will be launching an 'authorized generic' of genital herpes drug Zovirax ointment later in the day. The move comes a day after Mylan, Inc. (MYL) received final approval to launch Acyclovir Ointment USP, 5%, a generic version of Zovirax ointment.

"Yesterday, Mylan announced they had received approval of a generic Zovirax® ointment. While the timing of a generic approval was always uncertain, this was not unforeseen and we were prepared for its eventuality. In response to the new generic approval, we will be launching an authorized generic of Zovirax® ointment today," Valeant Chairman and CEO Michael Pearson said in a statement.

Meanwhile, the Mississauga, Ontario-based specialty pharmaceutical company said the Acyclovir launch is expected to negatively impact its fiscal 2013 cash earnings by about $0.30 to $0.40 per share. Valeant added it did not include the 'isolated event' in its original budget expectations.

However, the company noted it will likely mitigate the impact of the generic introduction with the positive effect of several product acquisitions, the repricing of term-loan debt and other events that have occurred since it provided financial guidance in January.

Valeant had revealed in January that it expected to post cash earnings in a range of $5.45 to $5.75 per share for fiscal 2013.

"We continue to expect once again to deliver outstanding performance in 2013 and we will provide an update to our 2013 guidance on our first quarter financial results conference call in May," Pearson added.

Zovirax Ointment is indicated as a treatment for initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients. Mylan's Acyclovir is the first generic version of Valeant's Zovirax Ointment.

According to IMS Health, Acyclovir Ointment USP, 5% had U.S. sales of about $230 million for the 12 months ended December 31, 2012. Mylan will start shipping Acyclovir Ointment immediately.

In Thursday's regular trading session, VRX is currently trading at $71.64, down $0.63 or 0.32% on a volume of 1.17 million shares. In the past 52-week period, the stock has been trading in a broad range of $42.47 to $76.56.

VRX.TO is currently trading on the TSX at $72.37, down $0.54 or 0.74% on a volume of 0.17 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Heading into a quiet week that precedes the final FOMC meeting of the year, the economic momentum remains strong. Data releases from the just concluded week makes it tough for the central bank to pass up an interest rate hike. However, will the Fed risk a backlash in a transition period on the political... AutoZone, Inc., an automotive replacement parts retailer, reported Tuesday higher profit in its first quarter with increased net sales and domestic store sales. Earnings per share topped analysts' estimates, while top line missed the view. In the pre-market activity on the NYSE, AutoZone shares were gaining 1.10 percent. The Justice Department, in the antitrust trial against the proposed Aetna- Humana Merger, argued that the merger would harm senior citizens who buy private Medicare plans. The U.S. Department of Justice stated that the merger would also harm consumers who buy plans on Affordable Care Act marketplaces, reports said. However, healthcare insurers Aetna And Humana defended their proposed merger..
comments powered by Disqus
Follow RTT